Panna Sharma, CEO of clinical stage oncology biotech Lantern Pharma, speaks to EPM about how his company’s artificial intelligence platform could help revolutionise drug development and ultimately change the way we treat cancer.
As a disease, cancer is perhaps both a patient’s and a clinician’s biggest fear.
For patients, a diagnosis of cancer often means undergoing invasive surgery to cut out whatever tumour resides inside them, alongside months or even years of body-wrecking chemotherapy. Often it means a death sentence.